MedPath

Effects of growth hormone (GH) replacement therapy in GH deficient adult childhood cancer survivors on organ size and microvascularisation of kidney and skin.

Conditions
growth hormone deficiency
10021112
10038430
Registration Number
NL-OMON33094
Lead Sponsor
ovo Nordisk
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

childhood cancer survivors who have been treated with cranial irradiation
growth hormone deficient
age > 18 years
> 5 years off tumor treatment

Exclusion Criteria

growth hormone replacement therapy in the last 12 months
current treatment for second malignancy
severe mental disorder/dementia/inability of legal consent
drug abuse/dependence
for women: pregnancy

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>1. Change in visceral organ size, especially kidney size.<br /><br>2. Change in GFR and ERPF.<br /><br>3. Change in capillary density of the skin.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Change in quality of life.</p><br>
© Copyright 2025. All Rights Reserved by MedPath